18F-FDG and 18F-Fluciclovine Uptake in Poorly Differentiated Lung Adenocarcinoma in the Setting of Biochemically Recurrent Prostatic Adenocarcinoma

Joseph Trak; Adnan Hasanovic; Somali Gavane

doi:10.1097/RLU.0000000000004387

18F-FDG and 18F-Fluciclovine Uptake in Poorly Differentiated Lung Adenocarcinoma in the Setting of Biochemically Recurrent Prostatic Adenocarcinoma

Clin Nucl Med. 2022 Dec 1;47(12):1077-1078. doi: 10.1097/RLU.0000000000004387. Epub 2022 Sep 6.

Authors

Joseph Trak¹, Adnan Hasanovic², Somali Gavane¹

Affiliations

¹ From the Division of Nuclear Medicine, Department of Radiology.
² Department of Pathology, Mount Sinai Hospital, New York, NY.

PMID: 36342794
DOI: 10.1097/RLU.0000000000004387

Abstract

A 64-year-old man with a history of Gleason 7 (3 + 4) pT2cN0 prostatic adenocarcinoma status post prostatectomy underwent a fluciclovine PET/CT that showed a tracer-avid right upper lobe spiculated solitary pulmonary nodule. Follow-up FDG PET/CT showed a hypermetabolic right upper lobe spiculated solitary pulmonary nodule. Fine-needle aspiration was consistent with primary lung adenocarcinoma. Subsequently, right upper lobectomy was performed, and poorly differentiated lung adenocarcinoma was confirmed.

Publication types

Case Reports

MeSH terms

Adenocarcinoma of Lung* / diagnostic imaging
Fluorodeoxyglucose F18
Humans
Lung Neoplasms* / diagnostic imaging
Male
Middle Aged
Neoplasm Recurrence, Local
Positron Emission Tomography Computed Tomography
Prostatic Neoplasms* / diagnostic imaging
Prostatic Neoplasms* / pathology
Radiopharmaceuticals
Solitary Pulmonary Nodule*

Substances

Fluorodeoxyglucose F18
Radiopharmaceuticals
fluciclovine F-18